Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | HINT1 | P49773 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 6/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198257 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL17198467 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL17198632 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL17198533 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL17198258 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL23187769 | 0.92 | POLB (0.57) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL29944545 | 0.92 | POLB (0.57) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL21162576 | 0.92 | POLB (0.57) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL22348826 | 0.92 | POLB (0.57) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 | |
| SCHEMBL25715926 | 0.92 | CYP3A4 (0.48) | CYP3A4CYP2C9POLBTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | CYP3A4 3319/4885CYP2C9 3771/4885POLB 430/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | CYP3A4 3291/4885CYP2C9 3724/4885POLB 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.